Expiration date: 10/2025

Composition

1 tablet contains active substance: Metformin hydrochloride 500 mg or 850 mg or 1000 mg

Pharmacotherapeutic group

Hypoglycemic means the group of biguanides for oral use 

Pharmacological action

Metformin decreases hyperglycemia without causing hypoglycemia. In contrast to derivatives of sulfonylurea, stimulates insulin secretion and has no 

hypoglycemic effect in healthy individuals. Increases 

the sensitivity of peripheral receptors to insulin and glucose utilization by cells. Inhibits gluconeogenesis in the liver. Delaying induction carbohydrates in the gut. Metformin stimulates the synthesis of glycogen, affecting glikogensintetazy. Increases transport capacity of all types of membrane glucose transporters. In addition, has a beneficial effect on lipid metabolism: reduces total cholesterol, low-density lipoprotein and triglycerides. On the background of Metformin the body weight of the patient either remains stable or moderately declining.

Indications for use

Diabetes type 2 diabetes, especially in patients with obesity, with poor diet and physical activity: in adults as monotherapy or in combination with other oral hypoglycemic agents, or insulin, in children from 10 years as monotherapy or in combination with insulin. 

Contraindications

Hypersensitivity to Metformin or to any auxiliary substance, diabetic ketoacidosis, diabetic precoma, coma, renal failure or impaired renal function (creatinine clearance (CC) less than 60 ml/min), acute conditions occurring with the risk of developing renal dysfunction: dehydration (diarrhea, vomiting), severe infectious diseases, shock, symptomatic manifestations of acute or chronic diseases that may lead to the development of tissue hypoxia (including cardiac or respiratory failure, acute myocardial infarction), extensive surgery and trauma, when is shown holding insulin, hepatic insufficiency, impaired liver function, chronic alcoholism, acute alcohol poisoning, pregnancy, lactic acidosis (including history), application in less than 48 hours prior to and for 48 hours after the radioisotope or radiological examinations with administration of iodinated contrast agents, compliance with a low calorie diet (less than 1000 kcal/day), children up to age 10 years.

Method of application and doses

The tablets should be taken orally, swallowed whole without chewing, during or immediately after a meal, squeezed enough water. Adults: monotherapy and combination therapy in combination with other oral hypoglycemic agents: the Usual starting dose is 500 mg or 850 mg 2-3 times per day after or during a meal. Possible further gradual increase in dose depending on the glucose concentration in the blood. Maintenance dose is usually 1500-2000 mg/day. To reduce the side effects from the gastrointestinal tract, the daily dose should be divided into 2-3 reception. The maximum dose is 3000 mg/day, in three divided doses. Slow increase of dose may improve gastrointestinal tolerability. Patients taking Metformin at doses of 2000-3000 mg/day, can be translated into the drug 1000 mg. the Maximum recommended dose of 3000 mg/day divided into 3 doses. In the case of planning the transition from receiving other hypoglycemic drugs: you must stop any other means and to start taking the drug Metformin in the dose mentioned above. 

Combination with insulin to achieve better glucose control, Metformin and insulin should be used in combination therapy. The usual starting dose of Metformin is 500 mg or 850 mg is one tablet 2-3 times a day, the drug of Metformin 1000 mg - one tablet 1 time per day, while the dose of insulin selected on the basis of the concentration of glucose in the blood. Children and teenagers: children from the age of 10 the drug Metformin can be used both in monotherapy and in 

combination with insulin. The usual starting dose is 500 mg or 850 mg 1 time per day after or during a meal. In 10 to 15 days the dose should be adjusted based on the concentration of blood glucose. The maximum daily dose is 2,000 mg divided into 2-3 doses. Elderly patients: because of the possible loss of kidney function the dose of Metformin should be selected under the regular monitoring of indicators of renal function (to determine the concentration of creatinine in serum at least 2-4 times a year). The duration of treatment determined by the physician. It is not recommended to interrupt taking the drug without advice of a physician.

Release form

Tablets 500 mg, 850 mg, 1000 mg, 30 or 60 tablets per pack